Clinical stages of dementia and the dexamethasone suppression test

Michael Serby, David Zucker, Michael Kaufman, Emile Franssen, Kamalamma Duvvi, Bart Rypma, John Rotrosen

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

1. 1. This study vas undertaken to evaluate the relationship between clinical aspects of primary degenerative dementia and suppression or non-suppression in the dexamethasone suppression test. 2. 2. We studied 34 male patients with primary degenerative dementia (as diagnosed by DSM-III criteria). Dexamethasone 1 mg p.o. was administered at 11:00 PM and blood was drawn for cortisol determination at 4:00 PM the next day. 3. 3. Clinical factors included: age, age at onset, duration of dementia, history of psychiatric illness, severity as measured by Global Deterioration Scale (GDS) score, and "malignancy" of dementia (rated by years of onset to institutionalization and as a ratio of Global Deterioration Scale to duration of primary degenerative dementia). 4. 4. Results: 56%. of primary degenerative dementia patients failed to suppress. The highest degree of non-suppression was seen in Global Deterioration Scale 5 and 6 subjects (Table). 5. 5. An unexpected finding was that a large number of Global Deterioration Scale 7 patients demonstrated normal post-dexamethasone suppresion of the hypothalmic-pituitary-adrenal axis. 6. 6. Some contradictions in previously reported studies may be explained by this pattern.

Original languageEnglish (US)
Pages (from-to)833-836
Number of pages4
JournalProgress in Neuropsychopharmacology and Biological Psychiatry
Volume12
Issue number5
DOIs
StatePublished - 1988

Keywords

  • cortisol
  • dementia
  • dexamethasone suppression test

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Fingerprint Dive into the research topics of 'Clinical stages of dementia and the dexamethasone suppression test'. Together they form a unique fingerprint.

Cite this